Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ARS Pharmaceuticals Inc shares valued at $724,345 were sold by Lowenthal Richard E on Aug 21 ’25. At $14.49 per share, Lowenthal Richard E sold 50,000 shares. The insider’s holdings dropped to 1,196,494 shares worth approximately $10.31 million following the completion of this transaction.
Also, Scott Kathleen D. sold 12,500 shares, netting a total of over 187,500 in proceeds. Following the sale of shares at $15.00 each, the insider now holds 10,042 shares.
Before that, Tanimoto Sarina had sold 37,656 shares from its account. In a trade valued at $530,626, the CHIEF MEDICAL OFFICER traded ARS Pharmaceuticals Inc shares for $14.09 each. Upon closing the transaction, the insider’s holdings decreased to 37,656 shares, worth approximately $10.75 million.
As published in their initiating research note from Roth Capital on September 04, 2025, ARS Pharmaceuticals Inc [SPRY] has been a Buy and the price target has been revised to $40. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in early March. As of February 10, 2025, Oppenheimer has initiated its “an Outperform” rating for SPRY. Earlier on August 20, 2024, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for SPRY stock.
Analyzing SPRY Stock Performance
On last trading session, ARS Pharmaceuticals Inc [NASDAQ: SPRY] plunged -4.01% to $8.62. The stock’s lowest price that day was $8.59, but it reached a high of $8.9999 in the same session. During the last five days, there has been a drop of approximately -10.67%. Over the course of the year, ARS Pharmaceuticals Inc shares have dropped approximately -42.49%. Shares of the company reached a 52-week high of $18.90 on 06/27/25 and a 52-week low of $8.59 on 10/30/25.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
According to the 24-hour chart, there is a support level at 8.47, which, if violated, would cause prices to drop to 8.33. In the upper region, resistance lies at 8.88. The next price resistance is at 9.15. RSI (Relative Strength Index) is 30.88 on the 14-day chart, showing neutral technical sentiment.
Is ARS Pharmaceuticals Inc subject to short interest?
Stocks of ARS Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-15 dropping by -2.62 million shares to 18.96 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 21.58 million shares. A decline of -13.81% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.21 of the overall float, the days-to-cover ratio (short ratio) decline to 7.21.
Which companies own the most shares of ARS Pharmaceuticals Inc (SPRY)?
In terms of ARS Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 32 in the next 12 months, up nearly 256.35% from the previous closing price of $8.98. Analysts anticipate ARS Pharmaceuticals Inc stock to reach 32 by 2025, with the lowest price target being 32. In spite of this, 4 analysts ranked ARS Pharmaceuticals Inc stock as Buy at the end of 2025. On August 13, 2024, Raymond James assigned a price target of “a Strong buy” to the stock and upgraded coverage with a $22.
